Lynparza (olaparib) vs Ibrance (palbociclib)

Lynparza (olaparib) is a PARP inhibitor used primarily for the treatment of certain types of advanced ovarian, breast, pancreatic, and prostate cancers in patients with specific genetic mutations (BRCA1/2 or other homologous recombination repair mutations). Ibrance (palbociclib), on the other hand, is a CDK4/6 inhibitor indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, typically in combination with hormonal therapies. The choice between Lynparza and Ibrance would depend on the cancer type, genetic profile of the tumor, hormone receptor status, and previous treatments, thus a healthcare provider would consider these factors and possibly conduct specific genetic testing before recommending the most appropriate therapy.

Difference between Lynparza and Ibrance

Metric	Lynparza (olaparib)	Ibrance (palbociclib)
Generic name	Olaparib	Palbociclib
Indications	Ovarian, breast, pancreatic, and prostate cancers with specific genetic mutations (BRCA1/2 or HRR gene mutations)	HR-positive, HER2-negative breast cancer in combination with specific endocrine therapies
Mechanism of action	Poly (ADP-ribose) polymerase (PARP) inhibitor, which leads to DNA damage in cancer cells	CDK4/6 inhibitor, which prevents cell division in cancer cells
Brand names	Lynparza	Ibrance
Administrative route	Oral	Oral
Side effects	Anemia, nausea, fatigue, vomiting, respiratory infections, blood count abnormalities	Neutropenia, leukopenia, infections, fatigue, nausea, stomatitis, anemia, hair loss
Contraindications	Hypersensitivity to olaparib or any component of the formulation	Hypersensitivity to palbociclib or any component of the formulation, severe hepatic impairment
Drug class	PARP inhibitor	CDK4/6 inhibitor
Manufacturer	AstraZeneca and Merck & Co. (MSD outside the US and Canada)	Pfizer

Efficacy

Lynparza (Olaparib) Efficacy in Breast Cancer

Lynparza, also known by its generic name olaparib, is a targeted therapy medication that has shown efficacy in the treatment of certain types of breast cancer. It belongs to a class of drugs known as PARP inhibitors, which work by preventing cancer cells from repairing their damaged DNA, leading to cell death. Lynparza is specifically approved for patients with HER2-negative breast cancer who have inherited mutations in the BRCA1 or BRCA2 genes. Clinical trials have demonstrated that Lynparza significantly extends progression-free survival in these patients compared to standard chemotherapy. This has established Lynparza as an important option for patients with BRCA-mutated, advanced breast cancer.

Ibrance (Palbociclib) Efficacy in Breast Cancer

Ibrance, or palbociclib, is another targeted therapy that has been shown to be effective in the treatment of breast cancer. It is a CDK4/6 inhibitor that works by interfering with the cell cycle, specifically by preventing cancer cells from progressing from the G1 phase to the S phase, which is necessary for DNA replication. Ibrance is approved for use in combination with certain hormone therapies for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Clinical studies have shown that Ibrance, when used in combination with letrozole or fulvestrant, improves progression-free survival in this patient population.

Comparative Efficacy in Breast Cancer

While both Lynparza and Ibrance are used in the treatment of breast cancer, their efficacy is tied to different subsets of the disease. Lynparza is most effective in patients with BRCA mutations, whereas Ibrance is used in HR+, HER2- breast cancer. The efficacy of these drugs is not directly comparable due to the distinct mechanisms of action and the specific patient populations they target. However, both drugs have significantly improved outcomes for their respective indications and represent advances in personalized cancer therapy.

Conclusion

In conclusion, both Lynparza and Ibrance have shown significant efficacy in the treatment of breast cancer, albeit in different subsets of patients. Lynparza is a valuable treatment for patients with BRCA-mutated breast cancer, while Ibrance has improved outcomes for those with HR+, HER2- disease when used in combination with hormone therapy. These medications exemplify the progress in targeted therapies that offer more personalized and effective treatment options for patients with breast cancer.

Regulatory Agency Approvals

Lynparza

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Ibrance

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Access Lynparza or Ibrance today

If Lynparza or Ibrance are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Lynparza

Buy Ibrance

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: